CBIO

13.1001.47%
RW

Richard William Scalzo

Chief Financial Officer

Mr. Richard William Scalzo, also known as Rick, M.B.A., is Chief Financial Officer of Crescent Biopharma, Inc. from April 2025. He was the Senior Vice President and Head of Finance & Administration at Dyne Therapeutics, Inc. since July 2022. He previously served as Vice President of Accounting and Administration at Dyne Therapeutics from January 2020 to June 2022 and was the Treasurer from August 2020 to June 2022. Mr. Scalzo also held the role of Corporate Controller at Dyne Therapeutics from December 2019 to July 2020, where he contributed significantly to the company's financial operations. With extensive experience in life sciences and public company finance, Mr. Scalzo has played key roles in several organizations. Prior to joining Dyne Therapeutics, he served as Corporate Controller at Kaleido Biosciences, Inc. from August 2018 to November 2019, where he was instrumental in the execution of the company’s Initial Public Offering (IPO) and led the transition of the accounting group from private to public company status. Before Kaleido, Mr. Scalzo was Corporate Controller at X4 Pharmaceuticals, Inc. from September 2016 to August 2018 and at Ocata Therapeutics, Inc. (acquired by Astellas Pharma Inc. in February 2016) from August 2014 to September 2016. At Ocata, he was a significant contributor to the company’s acquisition by Astellas Pharma and the subsequent integration of the two organizations. Mr. Scalzo began his career in public accounting with PricewaterhouseCoopers in its health industries practice. He is a certified public accountant in the Commonwealth of Massachusetts and holds a B.S. in Accounting from Boston College, as well as an MBA from the University of Massachusetts, Amherst.

Positions